基于乙基葡萄糖醛酸苷的列联管理治疗酒精使用障碍与严重精神疾病共病门诊患者的随机对照试验
结果显示列联管理组在12周干预期间提交EtG阴性尿检的可能性为对照组的3.1倍(95%CI=2.2-4.5),并多获得近1.5周酒精戒断。
要点
- 基于EtG的列联管理可提高共病严重精神疾病门诊患者的酒精戒断率
- 干预组在12周内提交EtG阴性尿检的可能性为对照组的3.1倍(95%CI=2.2-4.5)
- 自我报告的饮酒差异在3个月随访时仍维持
核心结论
- 基于EtG生物标志物的列联管理对共病严重精神疾病的酒精依赖门诊患者具有疗效。
研究设计与样本
- 随机分配至12周列联管理组(对EtG阴性尿样和成瘾治疗出勤给予强化)或仅对研究参与给予强化的对照组。
主要发现
- 列联管理组在12周干预期间提交EtG阴性尿检的可能性为对照组的3.1倍(95%CI=2.2-4.5)。
- 列联管理组比对照组多获得近1.5周酒精戒断。
- 列联管理组平均EtG水平显著更低,自我报告饮酒更少且重度饮酒次数更少。
- 列联管理组更可能提交兴奋剂阴性尿样和吸烟阴性呼气样本。
- 自我报告的饮酒差异在3个月随访时仍维持。
关键数值与推荐
- EtG阴性判定阈值为<150 ng/mL,每周检测三次。
- 列联管理包括基于EtG阴性样本的可变幅度强化「抽奖」程序,以及每周门诊治疗出勤礼品卡。
临床怎么用
- 对共病严重精神疾病与酒精依赖的门诊患者,可考虑使用基于EtG的列联管理以提高酒精戒断。
- 列联管理同时与刺激剂使用和吸烟的阴性检测结果相关,可综合关注多重物质使用。
局限性
- 随访期仅3个月,长期疗效未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors examined whether a contingency management intervention using the ethyl glucuronide (EtG) alcohol biomarker resulted in increased alcohol abstinence in outpatients with co-occurring serious mental illnesses. Secondary objectives were to determine whether contingency management was associated with changes in heavy drinking, treatment attendance, drug use, cigarette smoking, psychiatric symptoms, and HIV-risk behavior. METHOD: Seventy-nine (37% female, 44% nonwhite) outpatients with serious mental illness and alcohol dependence receiving treatment as usual completed a 4-week observation period and were randomly assigned to 12 weeks of contingency management for EtG-negative urine samples and addiction treatment attendance, or reinforcement only for study participation. Contingency management included the variable magnitude of reinforcement "prize draw" procedure contingent on EtG-negative samples (<150 ng/mL) three times a week and weekly gift cards for outpatient treatment attendance. Urine EtG, drug test, and self-report outcomes were assessed during the 12-week intervention and 3-month follow-up periods. RESULTS: Contingency management participants were 3.1 times (95% CI=2.2-4.5) more likely to submit an EtG-negative urine test during the 12-week intervention period, attaining nearly 1.5 weeks of additional alcohol abstinence compared with controls. Contingency management participants had significantly lower mean EtG levels, reported less drinking and fewer heavy drinking episodes, and were more likely to submit stimulant-negative urine and smoking-negative breath samples, compared with controls. Differences in self-reported alcohol use were maintained at the 3-month follow-up. CONCLUSIONS: This is the first randomized trial utilizing an accurate and validated biomarker (EtG) to demonstrate the efficacy of contingency management for alcohol dependence in outpatients with serious mental illness.
引用
- McDonell MG, Leickly E, McPherson S, et al. A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness. Am J Psychiatry. 2017. PMID: 28135843. doi:10.1176/appi.ajp.2016.16050627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。